High vWF levels, as seen in stroke and cardiovascular disease, could also be potentially mitigated by recombinant ADAMTS13 more safely than by plasma transfusion [81], thus showing the potential of this protein in biomedical applications. This evidence concerns the gene ADAMTS13 and Stroke.